Clinical trials: copd or chronic obstructive
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.
- Trial name
- INSIST (NCT00821093)
- Testing
- Indacaterol 150 µg, Salmeterol 50 µg
- Where
- 144 sites in United States, Czechia and 6 more
- Volunteers
- 1,123 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy
The purpose of this trial is to confirm if benralizumab can reduce the use of maintenance OCS in systemic corticosteroid dependent patients with severe refractory asthma with elevated eosinophils.
- Trial name
- NCT02075255
- Testing
- Benralizumab
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
Chronic Graft Versus Host Disease
Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
Chronic graft-versus-host disease (cGVHD) is a long-lasting complication that can occur after transplants. The transplanted cells seem to fight with the patient's own cells.
- Trial name
- NCT01380535
- Testing
- ECP Methoxsalen, Standard of Care
- Where
- 32 sites in United States, Austria and 6 more
- Volunteers
- 60 people
- Sponsor
- Mallinckrodt
Chronic Obstructive Pulmonary Disease, Lung Disease
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
The purpose of the study is to investigate the tolerability and safety of AZD2423 in Patients with chronic obstructive pulmonary disease.
- Trial name
- NCT01215279
- Testing
- AZD2423
- Where
- 6 sites in Bulgaria, Slovakia
- Volunteers
- 63 people
- Sponsor
- AstraZeneca
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks…
- Trial name
- PERFECT (NCT03496623)
- Testing
- Inhaled treprostinil solution
- Where
- 76 sites in United States, Argentina and 2 more
- Volunteers
- 188 people
- Sponsor
- United Therapeutics
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study.
- Trial name
- NCT02130557
- Testing
- Bosutinib, Imatinib
- Where
- 189 sites in United States, Australia and 24 more
- Volunteers
- 536 people
- Sponsor
- Pfizer
Pulmonary Disease, Chronic Obstructive
Tiotropium / Respimat One-Year Study
To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.
- Trial name
- NCT00168844
- Testing
- Tiotropium Inhalation Solution
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 983 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
- Trial name
- NCT00358436
- Testing
- Aclidinium bromide
- Where
- 120 sites in United States, Argentina and 5 more
- Volunteers
- 804 people
- Sponsor
- AstraZeneca
Psoriasis
Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
The primary objective of this trial is to evaluate the clinical efficacy and safety of two oral doses of MP1032 (150 mg bid and 300 mg bid) when taken for 12 weeks by patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT03706209
- Testing
- MP1032
- Where
- 19 sites in Germany, Poland
- Volunteers
- 155 people
- Sponsor
- MetrioPharm AG
Pulmonary Disease, Chronic Obstructive, COPD
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Stage 1 of the study is designed to provide data about the risk-benefit of 4 dose regimens of indacaterol (75, 150, 300 \& 600 µg o.d.) in order to select two doses to carry forward into study Stage 2.
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Trial name
- NCT00463567
- Testing
- Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.)
- Where
- 344 sites in United States, Argentina and 10 more
- Volunteers
- 2,059 people
- Sponsor
- Novartis
COPD
Efficacy and Safety of AQX-1125 in Unstable COPD
The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo in subjects following exacerbations of Chronic Obstructive Pulmonary Disease…
- Trial name
- FLAGSHIP (NCT01954628)
- Testing
- AQX-1125
- Where
- 8 sites in United States, Australia and 6 more
- Volunteers
- 400 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Chronic Obstructive Pulmonary Disease
A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients
This is a Phase 2a, proof-of-concept, multicenter, randomized, double-blind, double dummy, 3-treatment, parallel study, with low and high YPL 001 doses (low dose and high dose twice daily [BID]) and a placebo control in moderate…
- Trial name
- NCT02272634
- Testing
- YPL-001 80 mg, YPL-001 160 mg
- Where
- 4 sites in United States
- Volunteers
- 61 people
- Sponsor
- Yungjin Pharm. Co., Ltd.
COPD
7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
This study will characterize the dose response of TD-4208 after 7 days of dosing in subjects with Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT01704404
- Testing
- TD-4208
- Where
- New Zealand
- Volunteers
- 62 people
- Sponsor
- Mylan Inc.
Chronic Obstructive Pulmonary Disease
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
- Trial name
- NCT00419744
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
- Where
- 140 sites in United States, Argentina and 7 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Vibratory PEP Device and Hospital Length of Stay for Acute Exacerbation of COPD
This study is evaluating the use of a respiratory device, the Acapella Vibratory Positive Expiratory Pressure (PEP) Therapy device, in patients admitted to the hospital with a chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT03094806
- Testing
- Acapella Vibratory PEP Therapy Device plus usual care
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- New York Presbyterian Brooklyn Methodist Hospital
Hepatitis C Virus Infection
Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) for 8 weeks and of treatment with…
- Trial name
- POLARIS-3 (NCT02639338)
- Testing
- SOF/VEL/VOX, SOF/VEL
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
COPD
Study of Humidified Air to Improve Mucociliary Clearance (MCC) in COPD
This purpose of this study is to determine whether nasal delivery of heated and humidified air for a period of 4 hours will improve the clearance of mucus from the lungs of patients with chronic obstructive pulmonary disease…
- Trial name
- NCT03935932
- Testing
- nasal delivery of heated and humidified air
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Frank C Sciurba
Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at…
- Trial name
- NCT01186744
- Testing
- CP-690,550
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Healthy, Pulmonary Disease, Chronic Obstructive
Relative Bioavailability of of Olodaterol and Ketoconazole
This clinical trial is intended to investigate a possible effect of the p-gp inhibitor ketoconazole on the bioavailability of olodaterol
- Trial name
- NCT01153711
- Testing
- BI 1744, Ketoconazole
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients
This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic…
- Trial name
- NCT00224055
- Testing
- Sodium Ferric Gluconate Complex in Sucrose Injection, Ferrous sulfate tablets
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 89 people
- Sponsor
- Watson Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.